» Articles » PMID: 10569295

Major Bleeding After Hospitalization for Deep-venous Thrombosis

Overview
Journal Am J Med
Specialty General Medicine
Date 1999 Nov 24
PMID 10569295
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Most studies of oral anticoagulant-related bleeding have analyzed the incidence of adverse outcomes among patients with a variety of different conditions and without any comparison with a control group. We determined the incidence, time course, and risk factors associated with major bleeding after hospital discharge among patients with deep-vein thrombosis, and estimated the excess risk of bleeding associated with oral anticoagulant therapy.

Methods: A total of 22,000 adults were hospitalized in California for 3 or more days with a diagnosis of deep-venous thrombosis between January 1, 1992, and September 30, 1994. We determined the risk factors associated with readmission for bleeding. We compared the incidence of readmission for bleeding with comparison cohorts of patients with pneumonia or cellulitis who were matched for age, gender, race, and length of hospital stay.

Results: Of 21,250 patients with deep-venous thrombosis who were discharged without bleeding, 1.4% were readmitted for bleeding within 91 days; the rate was 2.7 times greater in the first 30 days than in the next 61 days. Risk factors for bleeding included hospitalization with gastrointestinal bleeding during the previous 18 months (relative hazard [RH] = 2.6, 95% confidence interval [CI]: 1.6 to 4.1), hospitalization with an alcohol-related diagnosis during the previous 18 months (RH = 2.6, 95% CI: 1.4 to 4.8), chronic renal disease (RH = 2.4, 95% CI: 1.4 to 4.2), female gender (RH = 1.7, 95% CI: 1.3 to 2.2), presence of a malignancy (RH = 1.6, 95% CI: 1.2 to 2.2), nonwhite race (RH = 1.6, 95% CI: 1.2 to 2.1), and age over 65 years (RH = 1.3, 95% CI: 1.0 to 1.7). Significantly more women (n = 40) had intracranial bleeding than men (n = 18, P = 0.02). In the comparison cohorts, the incidence of readmission for bleeding within 3 months of discharge was 0.7%, and the relative risk (RR) of readmission was greater in those with deep-venous thrombosis than in those with cellulitis (RR = 2.0, 95% CI: 1.6 to 2.5) or pneumonia (RR = 2.0, 95% CI: 1.7 to 2.5).

Conclusions: The incidence of rehospitalization for bleeding was greatest in the first 30 days after discharge, and was approximately twice that seen in patients hospitalized for cellulitis or pneumonia. Further studies are needed to determine why women and nonwhite patients are at increased risk for anticoagulant-related bleeding.

Citing Articles

Thrombin Generation Is Associated with Venous Thromboembolism Recurrence, but Not with Major Bleeding and Death in the Elderly: A Prospective Multicenter Cohort Study.

Vrotniakaite-Bajerciene K, Rutsche S, Calzavarini S, Quarroz C, Stalder O, Mean M J Clin Med. 2023; 12(18).

PMID: 37762997 PMC: 10531633. DOI: 10.3390/jcm12186050.


Association of race and in-hospital outcomes following acute pulmonary embolism: A retrospective cohort study.

Sullivan A, Barbery C, Holder T, Green C, Patel M, Thomas K Clin Cardiol. 2023; 46(7):768-776.

PMID: 37255216 PMC: 10352978. DOI: 10.1002/clc.24055.


Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease.

den Exter P, Woller S, Robert-Ebadi H, Masias C, Morange P, Castelli D J Thromb Haemost. 2022; 20(8):1910-1919.

PMID: 35735219 PMC: 9545751. DOI: 10.1111/jth.15776.


Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.

Maus M, Alexander S, Bishop M, Brudno J, Callahan C, Davila M J Immunother Cancer. 2020; 8(2).

PMID: 33335028 PMC: 7745688. DOI: 10.1136/jitc-2020-001511.


Assessing the accuracy of ICD-10 codes for identifying acute thromboembolic events among patients receiving anticoagulation therapy.

Lawrence K, Joos C, Jones A, Johnson S, Witt D J Thromb Thrombolysis. 2019; 48(2):181-186.

PMID: 31124033 DOI: 10.1007/s11239-019-01885-y.